GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tourmaline Bio Inc.
The shares of Tourmaline Bio, a biotech company focused on treating immune diseases, reflect the potential of its lead drug. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma immune
Tourmaline Bio is a biotech company focused on treating immune diseases, which is its sole segment. We classify it as part of the Pharma-Immune sector, and the chart below reflects the dynamics of this entire biotech field.
Broad Market Index - GURU.Markets
Tourmaline Bio is a biopharmaceutical company developing drugs to treat inflammatory and autoimmune diseases. Its innovations earn it a spot on the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the overall biotech sector.
Change in the price of a company, segment, and market as a whole per day
TRML - Daily change in the company's share price Tourmaline Bio Inc.
The volatility of Tourmaline Bio, a biotech focused on immunology, reflects the sector's high risks. Change_co is an immediate reaction to clinical trial news. This metric is the basis for analysis of the autoimmune drug development sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Tourmaline Bio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TRML, which focuses on immune disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tourmaline Bio is a biopharmaceutical company specializing in drugs for the treatment of inflammatory diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Tourmaline's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tourmaline Bio Inc.
Tourmaline is a biotech company working in the field of immunology. Its shares, like many companies in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Tourmaline Bio, Inc. is a clinical-stage biotech company developing drugs for the treatment of inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tourmaline Bio is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tourmaline Bio Inc.
Tourmaline, a biopharmaceutical company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its autoimmune disease treatments, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Tourmaline Bio, Inc. is a clinical-stage biotech company focused on developing treatments for immune and inflammatory diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how the potential of its lead drug for treating thyroid disease and other autoimmune disorders impacts its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tourmaline Bio is a biotech company developing drugs to treat immune diseases. Like many clinical-stage companies, its value is driven by research data. The overall market chart provides only background information, while Tourmaline's performance is driven by development news, which can trigger sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tourmaline Bio Inc.
Tourmaline Bio, a clinical-stage biotech focused on treating immune diseases, exhibits high volatility. Weekly stock performance depends on news about clinical trials and regulatory decisions, each of which could dramatically alter the outlook.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Tourmaline Bio, like other early-stage biotech companies, often moves in response to overall sector sentiment. The chart allows you to compare its volatility with the industry's overall performance, distinguishing reactions to general news from sharp movements driven by specific clinical trial data.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tourmaline Bio is a biotech company focused on treating immune diseases. Its shares exist in a world of their own, where research data is king. The chart shows that TRML's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
TRML - Market capitalization of the company Tourmaline Bio Inc.
Tourmaline Bio's market cap is a financial bet on thyroid disease treatment. This biotech company's stock price reflects the promise of its antibody for treating thyroid-related autoimmune disorders. Its performance is a barometer of progress in clinical trials and potential in the market where there is an unmet medical need.
TRML - Share of the company's market capitalization Tourmaline Bio Inc. within the market segment - Pharma immune
Tourmaline Bio is a clinical-stage biotech company focused on developing treatments for immune and inflammatory diseases. Its market capitalization reflects the potential of its lead drug candidate. This chart shows how investors assess its chances of success in this highly competitive pharmaceutical field.
Market capitalization of the market segment - Pharma immune
Tourmaline Bio is a biotech company focused on treating immune diseases. The chart below shows the overall market capitalization of this cutting-edge sector. Its dynamics reflect investors' high hopes for the development of new, more effective treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Tourmaline Bio is a biotech company focused on treating immune diseases. Its market capitalization, like that of many clinical-stage companies, is not a reflection of current sales, but rather a bet on scientific success by investors. Its dynamics reflect how the market views the potential of its developments.
Book value capitalization of the company, segment and market as a whole
TRML - Book value capitalization of the company Tourmaline Bio Inc.
For Tourmaline Bio, a biotech company, book value is the capital it raises for clinical research. The chart below shows its financial resources, not its manufacturing facilities. Its level is an indicator of its ability to fund the development of new drugs for immune diseases.
TRML - Share of the company's book capitalization Tourmaline Bio Inc. within the market segment - Pharma immune
Tourmaline Bio is a biotech company focused on treating immune diseases. Its primary asset is the rights to a promising drug. The company's tangible asset share will be low, typical for clinical-stage companies, where the focus is on research rather than manufacturing.
Market segment balance sheet capitalization - Pharma immune
Tourmaline Bio is a clinical-stage biotech focused on immune diseases. Its value is derived almost entirely from the intellectual property of its drugs in development. A book value chart will demonstrate how intangible its business is while awaiting breakthrough results.
Book value of all companies included in the broad market index - GURU.Markets
Tourmaline Bio's book value represents capital focused on treating inflammatory diseases. The company's assets primarily include the rights to a promising molecule and the financial resources to conduct its clinical trials. The chart shows the size of the financial base dedicated to the development of a new thyroid drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tourmaline Bio Inc.
Tourmaline Bio is a biotech company focused on treating immune diseases. Its book value is essentially cash on hand. Its market capitalization represents investors' bet on the success of its lead drug candidate. The chart reflects changing expectations for clinical trial results.
Market to book capitalization ratio in a market segment - Pharma immune
Tourmaline Bio is a biotech company focused on treating immune diseases. Its value is determined almost entirely by the potential of its lead drug candidate. The chart shows how market expectations for clinical trials and future commercial success compare to its minimum tangible assets.
Market to book capitalization ratio for the market as a whole
Tourmaline Bio is a biotech company focused on treating immune diseases. Its value depends almost entirely on the success of clinical trials for a key drug. This is a classic example of a business where market valuation is based on future expectations. The chart shows how far such a valuation can deviate from the current book value.
Debts of the company, segment and market as a whole
TRML - Company debts Tourmaline Bio Inc.
Tourmaline Bio, a clinical-stage biotech company, uses debt financing to develop its immunology drugs. This chart reflects the capital raised to conduct costly clinical trials. For a company with no revenue, this is a vital resource for advancing its research and development to the commercial stage.
Market segment debts - Pharma immune
Tourmaline Bio is a clinical-stage biotech company focused on treating immune diseases. For such companies, raising capital, including debt, is vital to fund long-term, expensive clinical trials. This chart allows you to assess how the company's financial strategy compares to the high risk and potential of its developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotech developing therapeutics for immune diseases. Funding is crucial at this stage. This chart shows whether the company is using debt financing. This is an important signal for investors: the absence of debt means less pressure and more time to successfully complete research.
Market segment debt to market segment book capitalization - Pharma immune
Tourmaline Bio is a clinical-stage biotech company focused on developing treatments for inflammatory and autoimmune diseases. This process requires significant investment. The chart shows the overall debt burden in the pharmaceutical industry, providing context for understanding Tourmaline's financial strategy as it prepares for potential drug approval.
Debt to book value of all companies in the market
Tourmaline Bio, a biotech company, requires significant funding. This chart shows the overall market leverage, reflecting risk appetite. It serves as an indicator of "financial weather": during periods of investor caution (which may coincide with a reduction in market debt), raising capital for risky research becomes more difficult.
P/E of the company, segment and market as a whole
P/E - Tourmaline Bio Inc.
Tourmaline Bio is a biotech company focused on treating immune diseases. For a company in clinical development, this chart reflects investor faith in science. Its value indicates how the market perceives the potential of its lead drug candidate to become a successful commercial product for the treatment of a wide range of diseases.
P/E of the market segment - Pharma immune
Tourmaline Bio is a representative of the biotech sector. This chart shows the average P/E for this industry. Comparing the company's P/E to this benchmark allows us to understand how highly the market values the potential of its immune-disease treatments compared to the average chances of success for other biotech companies.
P/E of the market as a whole
Tourmaline Bio is a biotech company developing drugs to treat immune diseases. Its main asset was acquired from Pfizer, providing some validation. The company's valuation depends on the success of clinical trials. This chart shows the market's risk appetite. It provides insight into how investors view the drug's prospects and whether the company is following general trends in immunology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotech company focused on the treatment of immune diseases, particularly thyroid disorders. This chart reflects investor expectations for the clinical trial results of its lead candidate. This valuation is based on the drug's potential to become a standard of care in a large market.
%20P%2FE%20Tourmaline%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tourmaline-Bio-Inc.&v=1772592514607 "Chart of the company's future (projected) P/E Tourmaline Bio Inc.")
Future (projected) P/E of the market segment - Pharma immune
Tourmaline Bio is a biotech company focused on developing treatments for immune and inflammatory diseases. This chart compares the company's future profitability expectations with those of the biopharmaceutical sector. It reflects investor optimism about its lead drug candidate and its potential in a multi-billion-dollar market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772592514664 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Tourmaline Bio is a clinical-stage biotech company focused on developing treatments for immune diseases. For companies like these, access to capital is vital. This chart, reflecting overall market sentiment, shows how willing investors are to invest in long-term, risky scientific projects, which will determine Tourmaline's future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772592514711 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotechnology company focused on developing treatments for immune diseases. The company's financial position is determined by its research and development (R&D) expenditures. This chart illustrates its financial position, where current clinical trial expenses are an investment in a potential future blockbuster drug.
Profit of companies in the market segment - Pharma immune
Tourmaline Bio is a biotech company developing drugs to treat inflammatory and autoimmune diseases. This graph, which displays the sector's total revenue, highlights the potential of new therapeutic targets. The success of Tourmaline's clinical programs could lead to the creation of new treatment standards and have a significant impact on the profitability of the entire pharmaceutical industry.
Overall market profit
Tourmaline Bio is a biotech company focused on developing treatments for immune diseases. Its value is determined solely by the potential of its lead drug and the results of clinical trials. It is a classic example of a company whose fate is decided in the lab and regulatory chambers, not by overall economic trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tourmaline Bio Inc.
Tourmaline Bio is a biotechnology company developing drugs to treat immune diseases. The future revenue projections you see are speculative and based on the potential of its lead candidate. Analyst expectations are based on clinical trial data and an estimated target market for the new drug.
%20profit%20of%20the%20company%20Tourmaline%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tourmaline-Bio-Inc.&v=1772592514865 "Graph of future (projected) profit of the company Tourmaline Bio Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Tourmaline Bio is a biotechnology company focused on developing treatments for inflammatory and immune diseases. This chart shows overall revenue forecasts for the entire immunotherapy segment. It reflects analysts' expectations for new treatment approaches for a wide range of conditions, from rheumatoid arthritis to thyroid disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772592514937 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Tourmaline Bio is a biotech company focused on treating immune diseases. Its value and prospects depend primarily on the success of clinical trials. However, overall market conditions, as reflected in this chart, impact the entire biotech sector. Positive economic forecasts facilitate raising capital for expensive R&D programs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772592514995 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotech company specializing in developing treatments for immune diseases. For a company on the path to commercializing its first drug, this chart is especially important. It reflects investor expectations for the future success of its developments, not current financial performance, which may never be achieved.
P/S market segment - Pharma immune
Tourmaline Bio is a clinical-stage biotech company focused on developing treatments for inflammatory and autoimmune diseases. Its lead candidate targets a broad range of indications. This chart reflects investor estimates of revenue in the immunology sector, helping to understand market expectations for the potential of Tourmaline's drugs to address significant medical needs.
P/S of the market as a whole
Tourmaline Bio is a clinical-stage biotech company focused on developing treatments for immune and inflammatory diseases. Its lead candidate targets a broad range of autoimmune disorders. This chart helps investors understand how the market views the potential of future pharmaceutical blockbusters against the backdrop of overall company revenue valuations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tourmaline Bio Inc.
Tourmaline Bio is a biotech company developing drugs to treat immune and inflammatory diseases. For a clinical-stage company, this chart shows the market's estimate of its potential future revenue. It reflects investor confidence in the success of its lead candidate and its commercial potential for treating thyroid diseases.
%20P%2FS%20Tourmaline%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tourmaline-Bio-Inc.&v=1772592515272 "The graph of the company's future (projected) P/S Tourmaline Bio Inc.")
Future (projected) P/S of the market segment - Pharma immune
Tourmaline Bio is a clinical-stage biotech focused on developing treatments for inflammatory and autoimmune diseases. This chart compares investor expectations for its future revenue with the sector. The high valuation reflects expectations for the success of its lead candidate, which could be a breakthrough in the treatment of thyroid diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772592515306 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Tourmaline Bio is a biotech company developing therapeutics for immune diseases. Its future depends on the success of clinical trials and the potential commercialization of its new drug. This graph of investor expectations reflects their risk appetite and belief that breakthroughs in immunology will create new multibillion-dollar markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772592515317 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotech company focused on immune diseases. Its revenue at this stage is generated not from product sales, but from strategic partnerships. This graph reflects the receipt of upfront or milestone payments, which confirm the value of its developments to major pharmaceutical players.
Sales of companies in the market segment - Pharma immune
Tourmaline Bio is a clinical-stage biotechnology company focused on developing drugs for the treatment of inflammatory and autoimmune diseases. The company targets key pathways in the immune system. This chart represents the total revenue of the entire immunology drug market, illustrating the enormous commercial potential for new treatments.
Overall market sales
Tourmaline Bio, Inc. is a biotech company specializing in developing treatments for immune diseases. Its valuation and prospects are determined by clinical trial results, not economic cycles. However, the overall economic situation, reflected in this chart, influences the availability of venture capital and the interest of large pharmaceutical companies in partnerships and acquisitions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotechnology company focused on developing treatments for immune and inflammatory diseases. Future revenue is dependent on the success of its lead candidate in clinical trials. This graph represents a long-term forecast based on potential market demand for new treatments.
%20sales%20of%20the%20company%20Tourmaline%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tourmaline-Bio-Inc.&v=1772592515487 "Schedule of future (projected) sales of the company Tourmaline Bio Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Tourmaline Bio is a biotech company specializing in developing treatments for immune diseases. This chart displays the projected revenue potential of their lead drug candidate. The data shows analysts' estimates of the market size and commercial prospects of their innovative therapy for patients with autoimmune disorders.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772592515547 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Investment activity in the pharmaceutical industry, closely linked to the forecasts in this chart, determines Tourmaline Bio's prospects. The biotech company, focused on immune diseases, relies on funding for clinical trials. Positive economic expectations are driving capital inflows into such risky projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772592515571 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotech company focused on treating immune diseases. This chart reflects its current status as a research-and-development organization. Negative values are typical, as the company is actively investing in clinical trials. Future profitability depends on the approval and commercial success of its lead drug.
Market segment marginality - Pharma immune
Tourmaline Bio is a biotechnology company specializing in the development of drugs for the treatment of inflammatory and immune diseases. Its future profitability depends on the success of clinical trials and the commercialization of its lead candidate. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing the potential and risks associated with Tourmaline's development.
Market marginality as a whole
Tourmaline Bio is a clinical-stage biotech company focused on treating immune diseases. Its future depends on the success of its trials and its ability to raise capital. This chart reflects overall investor sentiment and their willingness to invest in long-term, risky biotech projects, which is vital for funding Tourmaline's development.
Employees in the company, segment and market as a whole
Number of employees in the company Tourmaline Bio Inc.
Tourmaline Bio is a clinical-stage biotech focused on treating immune diseases. This graph reflects a compact team of scientists and managers advancing their lead candidate. Growth will likely be driven by the company's progression to later, larger-scale clinical trials, which will require expanded expertise and operational capabilities.
Share of the company's employees Tourmaline Bio Inc. within the market segment - Pharma immune
Tourmaline Bio is focused on developing drugs for the treatment of inflammatory and autoimmune diseases. Its key asset is its team of scientists working on targeted therapies. This chart shows Tourmaline's share of the total number of researchers in the field of immunology, reflecting its scientific potential and focus on solving complex medical problems.
Number of employees in the market segment - Pharma immune
Tourmaline Bio is a biotechnology company focused on developing treatments for immune and inflammatory diseases. This chart reflects activity in the immunology research sector. The growing number of scientists in this field indicates a high demand for new, more effective drugs to treat a wide range of autoimmune disorders, which is Tourmaline's mission.
Number of employees in the market as a whole
Tourmaline Bio is a biotechnology company focused on treating immune diseases. Their development depends on the success of clinical trials and strategic R&D decisions. This general work schedule does not affect their operations in any way. The growth of their team of scientists and doctors is dictated solely by the progress of their lead drug.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tourmaline Bio Inc. (TRML)
Tourmaline Bio is a clinical-stage biotech company specializing in immune diseases. Its valuation is based on the potential of its lead drug candidate. This chart typically shows a very high cost per employee for such companies, as investors value the science generated by a small, focused team.
%20of%20the%20company%20Tourmaline%20Bio%20Inc.%20(TRML)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tourmaline-Bio-Inc.-TRML&v=1772592516218 "Chart of market capitalization per employee (in thousands of dollars) of the company Tourmaline Bio Inc. (TRML)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Tourmaline Bio is a biotech company developing drugs to treat immune diseases. Like other R&D companies, their valuation is determined by the potential of their lead candidate (TOUR006). This indicator reflects the high market valuation of their IP based on their small scientific team.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772592516300 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Tourmaline Bio is a clinical-stage biotech focused on treating immune diseases. Its market cap is based on the potential of its lead drug candidate. This chart illustrates a typical biotech situation, where a huge market value accrues to a small team whose research success could lead to a new standard of treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772592516372 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tourmaline Bio Inc. (TRML)
Tourmaline Bio is a clinical-stage biotech focused on treating inflammatory and autoimmune diseases. Like most R&D companies without a product, this chart shows not profit but rather the company's "burn rate." It reflects how much the company invests (negative profit) per employee to conduct clinical trials.
%20Chart%20Tourmaline%20Bio%20Inc.%20(TRML)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tourmaline-Bio-Inc.-TRML&v=1772592516407 "Company Profit Per Employee (in thousands of dollars) Chart Tourmaline Bio Inc. (TRML)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Tourmaline Bio is a clinical-stage biotech company specializing in the treatment of autoimmune diseases (thyroid). This chart shows the benchmark for the "Biotech sector." In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by "profit," but by the "burn rate" of the R&D budget.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772592516432 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Tourmaline Bio is a biotech company focused on treating inflammatory and autoimmune diseases. Their lead candidate targets thyroid disease. This is classic biotech: R&D, clinical trials. This chart shows how this model, where all value is generated by the intellectual work of a small group of scientists, differs from the market average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772592516452 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tourmaline Bio Inc. (TRML)
Tourmaline Bio is a biotech company focused on treating immune diseases. Being in clinical development, the company has no commercial revenue from its products. This chart clearly demonstrates the company's zero or minimal revenue per employee, which is typical for R&D companies whose value lies in the potential of future drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tourmaline-Bio-Inc.-TRML&v=1772592516468 "Sales chart per company employee Tourmaline Bio Inc. (TRML)")
Sales per employee in the market segment - Pharma immune
Tourmaline Bio is a clinical-stage biotech company focused on treating inflammatory and autoimmune diseases. Their lead candidate targets thyroid disease. This graph reflects their R&D status. The productivity of their team of scientists and doctors lies in advancing the drug through the clinical trials, not in ongoing sales.
Sales per employee for the market as a whole
Tourmaline Bio (TRML) is a clinical-stage biotech company focused on developing therapeutics for inflammatory and autoimmune diseases. Like most clinical-stage biotechs, Tourmaline has no commercial products. This schedule will be zero or very low, reflecting milestone payments from partners (if any). The company's entire staff (primarily scientists) is currently a cost center.
Short shares by company, segment and market as a whole
Shares shorted by company Tourmaline Bio Inc. (TRML)
Tourmaline Bio is a clinical-stage biotech focused on treating autoimmune and inflammatory diseases. Their lead candidate targets thyroid disease. This chart shows the level of skepticism. High bearish sentiment reflects the risks of biotech: investors may be betting on failure in clinical trials, a long road to approval, or intense competition in the immunology field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tourmaline-Bio-Inc.-TRML&v=1772592516814 "Short Shares Chart for the Company Tourmaline Bio Inc. (TRML)")
Shares shorted by market segment - Pharma immune
Tourmaline Bio (TRML) is a clinical-stage biotech focused on treating inflammatory and autoimmune diseases (such as thyroid disease). This chart shows bets against the immune pharma sector. Shorts in this sector reflect general investor skepticism toward early-stage biotechs that require massive funding or doubts about the success of specific clinical trials.
Shares shorted by the overall market
Tourmaline Bio (TRML) is a clinical-stage biotech (immunology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives TRML of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tourmaline Bio Inc. (TRML)
Tourmaline Bio is a clinical-stage biotech company. Its shares are highly sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks or a general risk-aversion trend in biotech, indicating potential pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tourmaline-Bio-Inc.-TRML&v=1772592517337 "RSI 14 indicator chart for the company's stock Tourmaline Bio Inc. (TRML)")
RSI 14 Market Segment - Pharma immune
Tourmaline Bio is a clinical-stage biotech company developing a therapeutic (antibody) for the treatment of autoimmune and inflammatory diseases, particularly thyroid disease. This chart shows the overall sentiment in the immunology biotech sector. It clearly demonstrates when this entire niche is overhyped or oversold due to setbacks.
RSI 14 for the overall market
Tourmaline Bio (TRML) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TRML (Tourmaline Bio Inc.)
Tourmaline Bio is a biotech company focused on developing drugs to treat immune diseases, primarily thyroid eye disease (Graves' disease). This chart shows the average target price. Analysts' estimates are based on clinical data and the market potential of their lead candidate.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TRML-Tourmaline-Bio-Inc.&v=1772592517746 "A chart showing analyst consensus forecasts for the expected stock price. TRML (Tourmaline Bio Inc.)")
The difference between the consensus estimate and the actual stock price TRML (Tourmaline Bio Inc.)
Tourmaline Bio (TRML) is a biotech developing an anti-IL-6 therapy for the treatment of thyroid disease (TED) associated with the eye. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their lead candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TRML-Tourmaline-Bio-Inc.&v=1772592517905 "A chart showing the difference between the consensus forecast and the actual stock price. TRML (Tourmaline Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Tourmaline Bio is a late-stage biotech company repurposing an antibody (previously studied for other purposes) to treat thyroid eye disease and cardiovascular diseases. This chart shows the overall expectations for the immune pharma sector, reflecting whether experts believe in this approach.
Analysts' consensus forecast for the overall market share price
Tourmaline Bio (TRML) is an R&D biotech focused on immunology (thyroid, dry eye). They're burning money. This chart, reflecting expert expectations, is their risk appetite. When the market is pessimistic, investors flee cash-burning, pre-profit biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tourmaline Bio Inc.
Tourmaline Bio is a biotech company focused on treating autoimmune diseases. Their main asset (TOUR007) is an antibody targeting thyroid eye disease (TED). This chart is a pure indicator of their R&D pipeline. It likely aggregates their clinical trial data and market assessments of their chances in the highly competitive TED market.
AKIMA Market Segment Index - Pharma immune
Tourmaline Bio (TRML) is a clinical-stage biotech focused on immunology; the company is developing its candidate (an IL-6 inhibitor) for the treatment of thyroid eye disease (TED) (a competitor to Viridian). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this niche (TED) R&D focus (TRML) differentiate it from the average pharma company?
The AKIM Index for the overall market
Tourmaline Bio is a biotech company developing treatments for thyroid and cardiovascular diseases related to inflammation. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early-stage scientific story compares to the broader economic trends affecting biotech.
